Andrew John Armstrong, MD

Professor of Medicine
Associate Professor in Pharmacology and Cancer Biology
Professor in Surgery
Member of the Duke Cancer Institute
Campus mail Duke Box 103861, Durham, NC 27710
Phone (919) 668-8797
Email address

1. Predictors of sensitivity and clinical efficacy of therapies in advanced prostate cancer
2. Novel designs of clinical trials and pharmacodynamic/translational studies in prostate, kidney, bladder cancer
3. Pre-operative models for drug development of novel agents in human testing in prostate cancer
4. Novel therapies and drug development for prostate, renal, bladder, and testicular cancer
5. Design of rational combination therapies in men with metastatic hormone-refractory prostate cancer
6. PI3 kinase/mTOR inhibition in prostate cancer: mechanisms of sensitivity and resistance
7. Developing prognostic models for progression and survival in metastatic prostate cancer
8. Examining surrogate markers of mortality in metastatic prostate cancer
9. Clear cell and non-clear cell renal cell carcinoma: natural history, sensitivity to novel agents including mTOR and VEGF inhibition

In Their Words

Education and Training

  • Fellowship, Division Of Oncology/Hematology, Johns Hopkins University School of Medicine, 2003 - 2006
  • Internship/Residency, General Internal Medicine, University of Pennsylvania, School of Medicine, 2000 - 2003
  • M.Sc., Johns Hopkins University, 2008
  • M.D., University of Virginia School of Medicine, 2000
  • B.S.E., Duke University, 1996



Zhang, Tian, Anika Agarwal, R Garland Almquist, Daniella Runyambo, Sally Park, Elizabeth Bronson, Rengasamy Boominathan, et al. “Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer.” Biomark Res 9, no. 1 (February 18, 2021): 14.

Full Text

Armstrong, Andrew J., Andrew B. Nixon, Andrea Carmack, Timothy Eisen, Walter M. Stadler, Robert J. Jones, Jorge Garcia, et al. “Angiokines associated with outcomes after sunitinib or everolimus treatment in patients with non-clear cell renal cell carcinoma.” Clin Cancer Res, February 16, 2021.

Full Text

Armstrong, Andrew J., Xiaotong Li, Matthew Tucker, Shantao Li, Xinmeng Jasmine Mu, Kenneth Wha Eng, Andrea Sboner, Mark Rubin, and Mark Gerstein. “Molecular medicine tumor board: whole-genome sequencing to inform on personalized medicine for a man with advanced prostate cancer.” Prostate Cancer Prostatic Dis, February 10, 2021.

Full Text

Schaeffer, Edward, Sandy Srinivas, Emmanuel S. Antonarakis, Andrew J. Armstrong, Justin E. Bekelman, Heather Cheng, Anthony Victor D’Amico, et al. “NCCN Guidelines Insights: Prostate Cancer, Version 1.2021.” Journal of the National Comprehensive Cancer Network : Jnccn 19, no. 2 (February 2, 2021): 134–43.

Full Text

Marshall, Catherine H., Wei Fu, Hao Wang, Jong Chul Park, Theodore L. DeWeese, Phuoc T. Tran, Daniel Y. Song, et al. “Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate Cancer.” Clin Cancer Res, January 15, 2021.

Full Text

Shah, Anand, Thomas J. Polascik, Daniel J. George, John Anderson, Terry Hyslop, Alicia M. Ellis, Andrew J. Armstrong, et al. “Implementation and Impact of a Risk-Stratified Prostate Cancer Screening Algorithm as a Clinical Decision Support Tool in a Primary Care Network.” In J Gen Intern Med, 36:92–99, 2021.

Full Text

Armstrong, Andrew J., Neal D. Shore, Russell Z. Szmulewitz, Daniel P. Petrylak, Jeffrey Holzbeierlein, Arnauld Villers, Arun Azad, et al. “Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses.” In The Journal of Urology, 101097JU0000000000001568, 2020.

Full Text

Koontz, Bridget F., Karen E. Hoffman, Susan Halabi, Patrick Healy, Monika Anand, Daniel J. George, Michael R. Harrison, et al. “Combination of Radiation Therapy and Short-Term Androgen Blockade With Abiraterone Acetate Plus Prednisone for Men With High- and Intermediate-Risk Localized Prostate Cancer.” Int J Radiat Oncol Biol Phys, November 28, 2020.

Full Text

Shore, N. D., E. D. Crawford, R. Z. Szmulewitz, D. Petrylak, J. Holzbeierlein, A. Villers, A. Azad, et al. “Impact of baseline disease volume and prior docetaxel therapy on PSA-related outcomes in patients with mHSPC receiving enzalutamide plus ADT.” In Swiss Medical Weekly, 25S-26S, 2020.